Vitamin D testing and dose: what your 25(OH)D number means, how much D3 moves it, and why more is not better
Bottom line: Vitamin D3 has Grade B evidence for raising blood 25(OH)D in a dose-dependent manner and raises it more than D2, but routine testing of healthy people has not been shown to improve health.
The strongest finding is that daily vitamin D3 raises blood 25(OH)D in a predictable, dose-dependent way, with the biggest rise per unit at low doses: about 0.7 nmol/L for each extra microgram (40 IU) a day in a controlled winter trial (Heaney 2003), and 12 nmol/L per 1,000 IU a day at intakes up to 1,000 IU in records from 17,614 adults, falling to about 1 nmol/L per 1,000 IU at 15,000 to 20,000 IU (Ekwaru 2014). D3 raised levels more than D2 in a meta-analysis of head-to-head trials (Tripkovic 2012), and earlier benefit signals came from people who started low, though the 2025 update of the infection trials did not confirm a clearer benefit in that group. The evidence is weaker on testing and targets: no trial has shown that routine testing of healthy people improves health, and expert bodies disagree on the ideal level. Grade B.
Reviewed . We sell some of what we grade.

Editorial section. Research summaries are not product claims and contain no product links or offers. A summary is never proof that any product works.
- The question
- What blood level of 25-hydroxyvitamin D counts as low or adequate, should healthy adults get tested, how much does a daily dose of vitamin D3 raise the level, and what happened in trials of high daily doses or very large yearly doses?
- Study design
- Thresholds and testing: the 2011 Institute of Medicine (IOM) report on vitamin D requirements, based on bone health (Ross 2011), and the NIH Office of Dietary Supplements fact sheet that summarizes its cutoffs; the 2011 Endocrine Society guideline on evaluating and treating deficiency (Holick 2011); and the 2024 Endocrine Society guideline on vitamin D for generally healthy people (Demay 2024), built with GRADE methods from systematic reviews of placebo-controlled trials in people without an established reason for treatment or testing (Demay 2024). Dose response: 67 healthy men in Omaha given 0, 1,000, 5,000 or 10,000 IU of D3 a day for about 20 winter weeks (Heaney 2003); 22,214 records of supplement use and blood level from 17,614 Canadian adults in a preventive health program, analyzed by body weight (Ekwaru 2014); and a meta-analysis of randomized trials comparing D3 with D2 head to head (Tripkovic 2012). High doses: a 3-year double-blind trial in 311 healthy Canadians aged 55 to 70 with starting levels of 30 to 125 nmol/L, taking 400, 4,000 or 10,000 IU a day, with high-resolution bone scans (Burt 2019); and a double-blind trial in 2,256 women aged 70 or older at high fracture risk, given a single 500,000 IU dose or placebo each autumn or winter for 3 to 5 years (Sanders 2010). Dosing pattern: an individual participant data meta-analysis of 25 trials with 10,933 people on acute respiratory infections (Martineau 2017). [1][2][3][4][5][6][7][8][9][10][11]
- What they found
- What the number means: the 2011 IOM report set the adult RDA at 600 IU a day (800 IU from age 71), which corresponds to a 25(OH)D level of at least 50 nmol/L (20 ng/mL) and meets the needs of at least 97.5% of people, assuming minimal sun. NIH's summary of those cutoffs: below 30 nmol/L (12 ng/mL) carries a risk of deficiency, 30 to under 50 nmol/L (12 to under 20 ng/mL) is generally inadequate for bone health, 50 nmol/L (20 ng/mL) or more is adequate for most people, and above 125 nmol/L (50 ng/mL) is linked to potential adverse effects. The IOM committee found that higher levels were not consistently linked to more benefit, with U-shaped associations for some outcomes, and concluded that inadequacy in North America had been overestimated. To convert, 1 ng/mL equals 2.5 nmol/L. Testing: the 2011 Endocrine Society guideline suggested testing people at risk of deficiency, not screening everyone. The 2024 guideline found no trial evidence that routine 25(OH)D screening helps, including in people with obesity or darker skin, found no clear target level for preventing disease, and suggested against routine testing in all the groups it considered. It also suggested against intakes above the DRI for healthy adults under 75, and in favor of daily rather than intermittent high doses for people over 50 who need vitamin D. Dose response: in Heaney 2003, from a mean starting level of 70.3 nmol/L, blood levels rose by about 0.70 nmol/L for each extra microgram (40 IU) of D3 a day, roughly 17.5 nmol/L (7 ng/mL) per 1,000 IU. In Ekwaru 2014, the rise flattened as the dose went up (12.0 nmol/L per 1,000 IU between 0 and 1,000 IU a day, 1.1 nmol/L per 1,000 IU between 15,000 and 20,000 IU), and people with obesity and overweight averaged 19.8 and 8.0 nmol/L lower than normal-weight people. In Tripkovic 2012, D3 raised 25(OH)D more than D2 overall; the difference was clear with large single doses and not significant with daily dosing. High doses: in Burt 2019, levels at 3 years averaged 77 nmol/L on 400 IU, 132 nmol/L on 4,000 IU and 144 nmol/L on 10,000 IU. Radius bone density fell more on 4,000 IU (minus 2.4%) and 10,000 IU (minus 3.5%) than on 400 IU (minus 1.2%), tibia density fell more only on 10,000 IU, and bone strength did not differ between groups. Mild high blood calcium occurred in 9% of people on 10,000 IU, 4% on 4,000 IU and none on 400 IU, and high urine calcium in 33%, 22% and 17%; every high blood calcium episode resolved on retesting. In Sanders 2010, the yearly 500,000 IU dose increased falls (rate ratio 1.15) and fractures (rate ratio 1.26) compared with placebo, and falls were most frequent in the first 3 months after each dose. In Martineau 2017, daily or weekly vitamin D without large boluses lowered acute respiratory infections (odds ratio 0.81), regimens with one or more boluses did not (0.97), and among people on daily or weekly doses the effect was largest in those starting below 25 nmol/L (0.30); across all dosing patterns, people starting below 25 nmol/L had an odds ratio of 0.58. [1][2][3][4][5][6][7][8][9][10][11]
- Limitations
- The cutoffs come from bone health; nobody knows the best level for other outcomes, and the IOM, NIH and Endocrine Society statements were not designed to settle that. Lab tests for 25(OH)D vary, so a result can read falsely low or high depending on the method and the lab (NIH Office of Dietary Supplements); when you retest, use the same lab. Heaney 2003 studied only 67 men, over one winter, who already started near 70 nmol/L. Ekwaru 2014 is observational, relies on self-reported doses, and comes from a program that encourages supplementation; its data were provided by the Pure North S'Energy Foundation, which ran the program, and the authors declared no competing interests. Burt 2019 measured bone density with a research scanner, not fractures, in healthy adults who mostly had enough vitamin D to begin with; whether the lower density is harmful is unknown. It was funded by the Pure North S'Energy Foundation through an investigator-initiated grant, and the funder had no role in design, analysis or publication. Sanders 2010 tested one very large yearly dose in older women at high risk, so it does not describe modest daily doses. Tripkovic 2012 pooled trials with different doses and designs, and its authors called for more research across age, sex and ethnicity. Funding: the 2024 Endocrine Society guideline was funded by the Endocrine Society. Tripkovic 2012 had UK Medical Research Council, BBSRC and NIHR grants, and Martineau 2017 had NIHR and Medical Research Council funding. Funding for Heaney 2003 and Sanders 2010 was not stated in the abstracts we read.
- What this does not mean
- These studies do not show that vitamin D treats or prevents any disease, and the vitamin D3 in our Foundation multivitamin is not a treatment for deficiency; a diagnosed deficiency is managed by a clinician. The label claim is structure/function only: vitamin D supports bone health and normal immune function.* Since 18 Oct 2026 our independent grader grades this as two rows, both D: normal immune function when your level is low and bone health when your level is low, both tagged insufficient human evidence after the 2025 update of the infection trials (insufficient is not the same as evidence against). What we take from the evidence: if you have a medical reason to think you run low, such as a condition or surgery that limits fat absorption, ask your clinician whether a 25(OH)D blood test makes sense; the 2024 Endocrine Society guideline suggests against routine testing in generally healthy adults, including those with darker skin or obesity. Check the unit on your result (ng/mL or nmol/L). Big monthly or yearly doses are not better than a daily one, and for adults 50 and older who take vitamin D, the 2024 guideline prefers daily lower doses. If you retest, wait about three months, because the blood level takes weeks to settle (25(OH)D has a half-life of about 15 days), and use the same lab. Add up every source: the Foundation multivitamin, any D3 or D3 + K2 drops, fortified foods and any other supplement all count toward the adult upper limit of 4,000 IU a day, unless a clinician advises otherwise. Safety: too much vitamin D raises blood calcium, which can cause nausea, vomiting, muscle weakness, thirst and kidney stones, and in extreme cases kidney failure. NIH lists interactions with thiazide diuretics (risk of high calcium), steroids, orlistat and some statins. Talk to your clinician first if you have kidney disease or hyperparathyroidism, take a thiazide diuretic, or are pregnant or nursing. Vitamin K works against warfarin and similar anticoagulants, so anyone taking one should not start a K2 product without their clinician. For what the largest outcome trials found in people who already had enough, see vitamin-d-large-trials.
- Sources
- Ross AC et al. J Clin Endocrinol Metab. 2011;96(1):53-58. IOM 2011 report on calcium and vitamin D. doi.org/10.1210/jc.2010-2704 Our summary: The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know
- Holick MF et al. J Clin Endocrinol Metab. 2011;96(7):1911-1930. Endocrine Society guideline on deficiency. doi.org/10.1210/jc.2011-0385 Our summary: Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline
- Demay MB et al. J Clin Endocrinol Metab. 2024;109(8):1907-1947. Endocrine Society guideline on prevention. doi.org/10.1210/clinem/dgae290 Our summary: Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline
- Heaney RP et al. Am J Clin Nutr. 2003;77(1):204-210. D3 dose response over a winter. doi.org/10.1093/ajcn/77.1.204 Our summary: Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol
- Ekwaru JP et al. PLoS One. 2014;9(11):e111265. Dose response by body weight. doi.org/10.1371/journal.pone.0111265 Our summary: The Importance of Body Weight for the Dose Response Relationship of Oral Vitamin D Supplementation and Serum 25-Hydroxyvitamin D in Healthy Volunteers
- Tripkovic L et al. Am J Clin Nutr. 2012;95(6):1357-1364. D3 vs D2 meta-analysis. doi.org/10.3945/ajcn.111.031070 Our summary: Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis
- Burt LA et al. JAMA. 2019;322(8):736-745. 400 vs 4,000 vs 10,000 IU for 3 years. doi.org/10.1001/jama.2019.11889 Our summary: Effect of High-Dose Vitamin D Supplementation on Volumetric Bone Density and Bone Strength: A Randomized Clinical Trial
- Sanders KM et al. JAMA. 2010;303(18):1815-1822. Annual 500,000 IU dose. doi.org/10.1001/jama.2010.594 Our summary: Annual High-Dose Oral Vitamin D and Falls and Fractures in Older Women: A Randomized Controlled Trial
- Martineau AR et al. BMJ. 2017;356:i6583. Respiratory infections, daily vs bolus dosing. doi.org/10.1136/bmj.i6583 Our summary: Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
- NIH Office of Dietary Supplements: Vitamin D fact sheet for health professionals. ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
- NIH Office of Dietary Supplements: Vitamin K fact sheet for health professionals (updated 29 Mar 2021). ods.od.nih.gov/factsheets/VitaminK-HealthProfessional/
Why people take it
One row per claim you are likely to hear, each graded on its own. We never average them into one score.
This grade rates the published evidence for this molecule for this use. It does not rate our product, its quality or its testing.
A low grade doesn't mean the molecule is harmful or that you should stop taking it. It means the human evidence for that use is thin. Whether to take it is your call; our job is to show you what the studies found. This is not medical advice.
Bone health when your level is low: Grade D
Why this grade. Vitamin D is needed for bone, and severe deficiency can cause rickets and osteomalacia, which are diseases we do not grade. Pooled trials of vitamin D alone found no effect on fractures or falls and no clinically relevant change in bone density (Bolland 2018, 81 trials). In people starting at or below 30 nmol/L, exploratory or secondary analyses of two randomized trials found bone density benefits at the spine and hip (about 2% at the spine and femoral neck in Reid 2017, in a subgroup of 46 people (25 on 100,000 IU a month and 21 on placebo); Macdonald 2018, postmenopausal women on 400 or 1,000 IU a day), but we found no trial of vitamin D alone showing fewer fractures in people who start low. So the evidence for this use is insufficient, which is not the same as evidence against it. In one trial, 4,000 and 10,000 IU a day lowered radial bone density compared with 400 IU a day (Burt 2019). Vitamin D with calcium cut hip fractures in very old women in care homes, but that tested a combination (Chapuy 1992).
- Chapter: “Vitamin D deficiency: risks, why it's so common, & correcting with supplementation.” Rhonda Patrick, PhD, FoundMyFitness: #083 How Vitamin D, Omega-3s, & Exercise May Increase Longevity, , at 1:10.
Key evidence: Bolland MJ et al. Lancet Diabetes Endocrinol. 2018;6(11):847-858 (fractures, falls and bone density); Ross AC et al. J Clin Endocrinol Metab. 2011;96(1):53-58 (IOM report); Reid IR et al. J Intern Med. 2017;282(5):452-460 (bone density by starting level, exploratory); Macdonald HM et al. J Bone Miner Res. 2018;33(8):1464-1469 (secondary analysis); Burt LA et al. JAMA. 2019;322(8):736-745; Chapuy MC et al. N Engl J Med. 1992;327(23):1637-1642 (vitamin D3 with calcium); NIH Office of Dietary Supplements: Vitamin D fact sheet.
Normal immune function when your level is low: Grade D
Why this grade. In the 2025 update of the infection trials, vitamin D did not significantly reduce acute respiratory infections in people starting below 25 nmol/L (odds ratio 0.98, 95% CI 0.80 to 1.20; 22 trials, 3,806 people), and the review found no evidence that the effect differed by starting level, age, dose or dosing frequency. The earlier 2017 finding of protection in people starting low was not confirmed. The confidence interval is compatible with a meaningful benefit or harm, so this is not proof of zero effect. The same review reported protection in some dose and age subsets, including daily dosing, that its test for a difference did not confirm. Vitamin D is involved in immune function, but these trials measured respiratory infections, not normal immune function as a whole. They do not establish a benefit in people starting low, and they are not evidence against the label claim either: for this use, the human evidence is insufficient. This grade is about what a supplement was shown to add.
Key evidence: Jolliffe DA et al. Lancet Diabetes Endocrinol. 2025;13(4):307-320; Martineau AR et al. BMJ. 2017;356:i6583; Jolliffe DA et al. BMJ. 2022;378:e071230 (CORONAVIT); NIH Office of Dietary Supplements: Vitamin D fact sheet. Full article: Vitamin D and respiratory infections.
Living longer: Grade D
Why this grade. In the D-Health trial, monthly vitamin D for 5 years in 21,315 adults aged 60 and older did not lower deaths from any cause (hazard ratio 1.04, 95% CI 0.93 to 1.18). In VITAL, 2,000 IU a day for a median of 5.3 years in 25,871 adults also did not (hazard ratio 0.99, 95% CI 0.87 to 1.12). Neither trial selected people for a low starting level.
Key evidence: Neale RE et al. Lancet Diabetes Endocrinol. 2022;10(2):120-128; Manson JE et al. N Engl J Med. 2019;380(1):33-44.
Raising a low vitamin D level: Grade A
Why this grade. Randomized trials consistently show that a vitamin D supplement raises 25-hydroxyvitamin D in blood. Across 49 European trials (7,320 adults), the mean rise versus placebo was 36 nmol/L, and a global review of 136 trials found a clear dose response. These trials tested vitamin D itself, often at doses above the amount in a typical daily multivitamin, and a higher blood level is a status result, not a disease result.
Key evidence: Rupprecht M et al. Nutrients. 2023;15(18):3986; Mo M et al. Eur J Clin Nutr. 2019;73(6):816-834.
Muscle strength and physical performance, with no consistent gain: Grade B
Why this grade. Results conflict, and they do not show a consistent gain. A 2014 meta-analysis of 30 trials (5615 people) found a small gain in overall muscle strength (standardized mean difference 0.17), more marked when the starting 25-hydroxyvitamin D level was under 30 nmol/L, and no clear change in muscle mass or power. A later meta-analysis of 54 placebo-controlled trials (8747 people) found no benefit, including in studies with low vitamin D levels, and two measures were slightly worse. In athletes, 13 trials raised the blood level, but physical performance did not improve over 12 weeks.
Key evidence: Bislev LS et al. J Bone Miner Res. 2021;36(9):1651-1660; Beaudart C et al. J Clin Endocrinol Metab. 2014;99(11):4336-4345; Farrokhyar F et al. Sports Med. 2017;47(11):2323-2339.
Quoted for accuracy. No one quoted here endorses Everstack, is affiliated with us or is paid by us. A famous name never raises a grade. All claims we track · Grade change log
Related summaries
Spot an error? Email hello@everstackhealth.com and we will correct it within 48 hours.